Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party

被引：14

作者：

Horstmann, K. ^{[1
,2
]}

Boumendil, A. ^{[1
]}

Finke, J. ^{[3
]}

Finel, H. ^{[1
]}

Kanfer, E. ^{[4
]}

Milone, G. ^{[5
]}

Russell, N. ^{[6
]}

Bacigalupo, A. ^{[7
]}

Chalandon, Y. ^{[8
,9
]}

Diez-Martin, J. L. ^{[10
]}

Ifrah, N. ^{[11
]}

Jurado Chacon, M. ^{[2
,12
]}

Dreger, P. ^{[1
,2
]}

机构：

[1] EBMT Lymphoma Working Party, Paris, France

[2] Heidelberg Univ, Dept Med 5, D-69120 Heidelberg, Germany

[3] Univ Freiburg, Dept Med 1, D-79106 Freiburg, Germany

[4] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London, England

[5] Azienda Osped Policlin Vittorio Emanuele, Programma Trapianto Emopoiet, Catania, Italy

[6] Univ Nottingham Hosp, Ctr Clin Hematol, Nottingham NG7 2UH, England

[7] IRCCS San Martino, Div Hematol & Bone Marrow Transplantat, Genoa, Italy

[8] Univ Hosp Geneva, Div Hematol, Dept Med Specialties, Geneva, Switzerland

[9] Univ Geneva, Fac Med, Geneva, Switzerland

[10] HGU Gregorio Maranon, Dept Hematol & Hemotherapy, Madrid, Spain

[11] CHRU, Serv Malad Sang, Angers, France

[12] Hosp Univ Virgen Ias Nieves, Granada, Spain

来源：

BONE MARROW TRANSPLANTATION | 2015年 / 50卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; EUROPEAN GROUP; MARROW-TRANSPLANTATION; SOCIETE-FRANCAISE; ACUTE-LEUKEMIA; RISK; STRATEGY; BLOOD; INFUSIONS; SURVIVAL;

D O I：

10.1038/bmt.2015.12

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients >= 18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular if relapse occurs late and is chemosensitive.

引用

页码：790 / 794

页数：5

共 50 条

[31] Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT
Leyre Bento
Ariane Boumendil
Hervé Finel
Irma Khvedelidze
Didier Blaise
Nathalie Fegueux
Luca Castagna
Edouard Forcade
Patrice Chevallier
Nicola Mordini
Pauline Brice
Eric Deconinck
Martin Gramatzki
Paolo Corradini
Mathilde Hunault
Maurizio Musso
Anna Tsoulkani
Dolores Caballero
Sandro Nati
Silvia Montoto
Anna Sureda
Bone Marrow Transplantation, 2021, 56 : 655 - 663
[32] Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT
Craddock, Charles
Versluis, Jurjen
Labopin, Myriam
Socie, Gerard
Huyn, Anne
Deconinck, Eric
Volin, Liisa
Milpied, Noel
Bourhis, Jean Henri
Rambaldi, Alessandro
Chevallier, Patrice
Blaise, Didier
Markus, Manz
Vellenga, Edo
Vekemans, Marie Christiane
Maertens, Johan
Passweg, Jakob R.
Schmid, Christoph
Ossenkoppele, G. J.
Vyas, Paresh
Lowenberg, Bob
Mohty, Mohamad
Cornelissen, Jan J.
Nagler, Arnon
BLOOD, 2016, 128 (22)
[33] Haplotransplants versus other alternative donors for allogeneic stem cell transplantation in Non Hodgkin Lymphoma (NHL): A retrospective analysis of the EBMT Lymphoma Working Party
Dietrich, S.
Finel, H.
Martinez, C.
Tischer, J.
Blaise, D.
Milpied, N.
Bacigalupo, A.
Corradini, P.
Mohty, M.
Sanz, M.
Velardi, A.
Hausmann, A.
Montoto, S.
Hermine, O.
Schmitz, N.
Schouten, H.
Sureda, A.
Tanase, A.
Robinson, S.
Dreger, P.
BONE MARROW TRANSPLANTATION, 2015, 50 : S4 - S4
[34] Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party
Dietrich, Sascha
Finel, Herve
Martinez, Carmen
Tischer, Johanna
Blaise, Didier
Chevallier, Patrice
Castagna, Luca
Milpied, Noel
Bacigalupo, Andrea
Corradini, Paolo
Mohty, Mohamad
Sanz, Miguel A.
Velardi, Andrea
Hausmann, Andreas
Montoto, Silvia
Hermine, Olivier
Schmitz, Norbert
Schouten, Harry C.
Sureda, Anna
Tanase, Alina
Robinson, Stephen
Dreger, Peter
BLOOD, 2014, 124 (21)
[35] Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
Mitja Nabergoj
Katya Mauff
Marie Robin
Nicolaus Kröger
Emanuele Angelucci
Xavier Poiré
Jakob Passweg
Aleksandar Radujkovic
Uwe Platzbecker
Stephen Robinson
Alessandro Rambaldi
Søren Lykke Petersen
Fridrich Stölzel
Matthias Stelljes
Fabio Ciceri
Jiri Mayer
Marco Ladetto
Liesebeth C. de Wreede
Linda Koster
Patrick J. Hayden
Tomasz Czerw
Juan Carlos Hernández-Boluda
Donal McLornan
Yves Chalandon
Ibrahim Yakoub-Agha
Bone Marrow Transplantation, 2021, 56 : 1944 - 1952
[36] Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT
Chevallier, Patrice
Labopin, Myriam
Buchholz, Stefanie
Ganser, Arnold
Ciceri, Fabio
Lioure, Bruno
Faul, Christoph
Guillerm, Gaelle
Finke, Juergen
Huynh, Anne
Schubert, Joerg
Kolb, Hans Jochem
Polge, Emmanuelle
Nagler, Arnon
Mohty, Mohamad
BLOOD, 2011, 118 (21) : 1294 - 1294
[37] Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
Nabergoj, Mitja
Mauff, Katya
Robin, Marie
Kroeger, Nicolaus
Angelucci, Emanuele
Poire, Xavier
Passweg, Jakob
Radujkovic, Aleksandar
Platzbecker, Uwe
Robinson, Stephen
Rambaldi, Alessandro
Petersen, Soren Lykke
Stoelzel, Fridrich
Stelljes, Matthias
Ciceri, Fabio
Mayer, Jiri
Ladetto, Marco
de Wreede, Liesebeth C.
Koster, Linda
Hayden, Patrick J.
Czerw, Tomasz
Carlos Hernandez-Boluda, Juan
McLornan, Donal
Chalandon, Yves
Yakoub-Agha, Ibrahim
BONE MARROW TRANSPLANTATION, 2021, 56 (08) : 1944 - 1952
[38] Haploidentical donors for allogeneic stem cell transplantation in Hodgkin lymphoma (HL): a retrospective analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)
Martinez, C.
Gayoso, J.
Canals, C.
Finel, H.
Bacigalupo, A.
Peggs, K.
Milpied, N.
Ciceri, F.
Socie, G.
Corradini, P.
Robinson, S.
Velardi, A.
Fegueux, N.
Gutierrez-Garcia, G.
Mackinnon, S.
Potter, M.
Afanasyev, B.
Sierra, J.
Malladi, R.
Sanz, M. A.
Russell, N. H.
Arcese, W.
Dreger, P.
Sureda, A.
BONE MARROW TRANSPLANTATION, 2016, 51 : S153 - S153
[39] The impact of advanced patient age on mortality after allogeneic hematopoietic stem cell Transplantation (alloHSCT) for Non-Hodgkin's Lymphoma (NHL): A retrospective study by the EBMT Lymphoma Working Party
Kyriakou, C.
Boumendil, A.
Finel, H.
Schmitz, N.
Mackinnon, S.
Lenhoff, S.
Fegueux, N.
Or, R.
Volin, L.
Sengeloev, H.
Blaise, D.
Chevallier, P.
Browne, P.
Craddock, C.
Niederwieser, D.
Pagliuca, A.
Bornhaeuser, M.
Dreger, P.
BONE MARROW TRANSPLANTATION, 2016, 51 : S69 - S70
[40] REDUCED INTENSITY ALLOGENEIC SCT ACHIEVES LONG TERM DISEASE CONTROL IN PATIENTS WITH FOLLICULAR LYMPHOMA RELAPSING AFTER A PRIOR AUTOLOGOUS SCT AND MAY OVERCOME THE ADVERSE IMPACT OF EARLY RELAPSE POST AUTOSCT. AN EBMT LYMPHOMA WORKING PARTY ANALYSIS
Robinson, S. Paul
Boumendil, A.
Finel, H.
Schouten, H.
Maertens, J.
Sureda, A.
Rambaldi, A.
Wahlin, A.
Blaise, D.
Deconinck, E.
Cordonnier, C.
Yakoub-Agha, I.
Volin, L.
Vitek, A.
Russell, N.
Ganser, A.
Veelken, J.
Vandenberghe, E.
Faber, E.
Montoto, S.
Dreger, P.
BONE MARROW TRANSPLANTATION, 2014, 49 : S59 - S59

← 1 2 3 4 5 →